Cancer Research UK and Nxera Pharma launch Phase 1/2a trial of oral EP4 antagonist HTL0039732 for various cancers, led by Dr. Basu and Dr.
Nxera Pharma and Cancer Research UK are conducting a Phase 1/2a clinical trial for HTL0039732, an oral EP4 antagonist aimed at treating various cancers. The trial, which began in August 2023, assesses the drug's safety, tolerability, and effectiveness both alone and with atezolizumab. The research is led by Dr. Bristi Basu and Dr. Debashis Sarker, with findings to be presented at the upcoming ESMO Congress. Enrollment is ongoing.
September 13, 2024
5 Articles